Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Y1RO
|
||||
Former ID |
DNC003396
|
||||
Drug Name |
Novo Nordisk a/S Compound
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [551393] | ||
Structure |
Download2D MOL |
||||
Formula |
C9H6INO5
|
||||
Canonical SMILES |
C1=CC(=C(C=C1I)C(=O)O)NC(=O)C(=O)O
|
||||
InChI |
1S/C9H6INO5/c10-4-1-2-6(5(3-4)8(13)14)11-7(12)9(15)16/h1-3H,(H,11,12)(H,13,14)(H,15,16)
|
||||
InChIKey |
SHSWHSQPJKMCPN-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | mRNA of Protein tyrosine phosphatase-1B | Target Info | Inhibitor | [551393] | |
KEGG Pathway | Adherens junction | ||||
Insulin signaling pathway | |||||
NetPath Pathway | FSH Signaling Pathway | ||||
PANTHER Pathway | Cadherin signaling pathway | ||||
Pathway Interaction Database | Insulin Pathway | ||||
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||||
Signaling events mediated by PTP1B | |||||
Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
Signaling events mediated by TCPTP | |||||
IGF1 pathway | |||||
EGF receptor (ErbB1) signaling pathway | |||||
Posttranslational regulation of adherens junction stability and dissassembly | |||||
PDGFR-beta signaling pathway | |||||
N-cadherin signaling events | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.